Analysis File of Drug-Induced Lung Injury

Expert Opinion for Analysis of Big Data

Akihiko Gemma (Autor)

Buch | Hardcover

116 Seiten

2024 | 2024 ed.
Springer Nature (Verlag)
978-981-97-3445-0 (ISBN)

Artikel merken

This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.

Akihiko GemmaPresident, Nippon Medical School 1983:Graduated from the Faculty of Medicine of Nippon Medical School1986:Served as a trainee doctor in the Pathology Department of the National Cancer Center Research Institute1989:Graduated from Nippon Medical School Graduate School1995:Studied at National Cancer Institute of National Institutes of Health (NIH), the United States1998:Appointed as a lecturer to Nippon Medical School2004:Appointed as an associate professor2008:Appointed as a senior professor to the Department of Medicine (Respiratory, Infectious Disease and Oncology Division)2012:Appointed as a professor to the Graduate School of Medicine in charge of respiratory medicine2013:Appointed dean of Department of Medicine2015：Appointed president

Part I Understanding Drug-Induced Lung Injuries.- 1 Understanding Drug-Induced Lung Injuries.- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug.- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib).- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab).- 4 mTOR inhibitors (temsirolimus, everolimus).- 5 Proteasome inhibitor (bortezomib).- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab).- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab).- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.).- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan).- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.).

Erscheinungsdatum	26.08.2024
Zusatzinfo	18 Illustrations, color; 30 Illustrations, black and white; XII, 116 p. 48 illus., 18 illus. in color.
Verlagsort	Singapore
Sprache	englisch
Maße	155 x 235 mm
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Pneumologie
Themenwelt	Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik
Schlagworte	Anti-tumor agents • Big Data • Drug-induced • Drug induced interstitial lung disease • lung disorder • pathologic conditions • risk factor
ISBN-10	981-97-3445-2 / 9819734452
ISBN-13	978-981-97-3445-0 / 9789819734450
Zustand	Neuware